The Perfect Storm of Heart Failure and Diabetes: Insights into Pathophysiology and Evidence Based Treatment Strategies

Credits: None available.

The Perfect Storm of Heart Failure and Diabetes: Insights into Pathophysiology and Evidence-Based Treatment Strategies

An online educational activity based on a CME Satellite Symposium presented at the 20h Annual Meeting of the Heart Failure Society of America in Orlando, FL.

This activity is intended for cardiovascular specialists, cardiovascular nurses and nurse practitioners, pharmacists, scientist and other healthcare professionals caring for patients with heart failure.

Date of Release: December 1, 2016
Program End Date: November 30, 2017

Learning Objectives:
Upon completion of this activity, participants will be able to:

  • Explain the bidirectional association of diabetes and heart failure and the pathophysiology of heart failure in patients with diabetes.
  • Discuss prudent heart failure treatment strategies in patients with diabetes.
  • Assess the benefit-risk profiles of antidiabetic therapies in patients with/at risk for cardiovascular disease and interpret heart failure related outcomes.

Accreditation Statement
Physician: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The Heart Failure Society of America designates this online activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Content - The Perfect Storm of Heart Failure and Diabetes: Insights into Pathophysiology and Evidence-Based Treatment Strategies

Welcome and Introduction

Heart Failure in Diabetes: Pathophysiology, Outcomes, and Effects of Heart Failure Therapies
Gregg Fonarow, MD

Antidiabetic Agents and Heart Failure: Surveying the Data
Darren McGuire, MD, MHSc

Question and Answer
All Faculty

Disclosures
As a provider accredited by ACCME, HFSA ensures balance, independence, objectivity and scientific rigor in its educational activities. Course Directors, planning committee members, and speakers are required to disclose all relevant financial relationships. Faculty will also disclose off‐label or investigational uses of pharmaceuticals or devices discussed in their presentations. All potential conflicts have been resolved in accordance with ACCME guidelines for commercial support and content validation.

Speaker Disclosures:
Gregg Fonarow, MD, has disclosed the following relevant financial relationships: Research Grants: National Institute of Health (NIH). Consultant/Advisory Board: Amgen Inc.; Janssen Pharmaceuticals, Inc.; Medtronic; and Novartis Pharmaceuticals Corporation; St. Jude; and ZS Pharma

Darren McGuire, MD, MHSc Consultant/Advisory Board: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company. GalxoSmthKline, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi-Aventis

HFSA Reviewer Disclosures:
John Burnett, Jr., MD, has disclosed no relevant financial relationships.

Mona Fiuzat, PharmD, has disclosed no relevant financial relationships.

Kenneth Margulies, MD, has disclosed the following relevant financial relationships: Research Grants: CardioCell, LLC; Merk; Sharp and Dohme; and St. Lukes Hospital (Kansas City) Consultant/Advisory Board: GlaxoSmithKline; Merk; Janssen Pharmaceuticals, Inc.; and Sharp and Dohme.

Debra Moser, DNSc, RN, has disclosed no relevant financial relationships.

Marc Semigran, MD, has disclosed the following relevant financial relationships: Research Grants: CVRx. Inc.; St. Jude Medical; and Novartis Pharmaceuticals Corporation. Consultant/Advisory Board: Amgen Inc.; and Broadview.

David Whellan, MD, has disclosed no relevant financial relationships.

Jaime Abreu, MBA, has disclosed no relevant financial relationships.

Voxmedia Disclosures:
John Kocsis, PhD – President

Commercial Support
Support for this enduring activity was provided through an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Method of Participation and CME Certificate
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

To receive CME credit for this product, the participant must:

  1. Read the CME Information including target audience, learning objectives, and faculty disclosures.
  2. Complete the pre-test.
  3. View the presentations.
  4. Complete the post-test and evaluation by choosing the best answer to each question. You must score 80% or higher on the post-test. You will have the opportunity to re-take questions missed until the 80% score is achieved.

After successfully completing the post-test and evaluation, your CME certificate will be generated and immediately available for print.

Medium or Combination of Media Used
This enduring activity is available in these format offerings:

  • Online access via the HFSA Website under Online Education
  • Downloadable MP3 files
  • Mobile version for most mobile devices

Provider Contact information
Heart Failure Society of America
6707 Democracy Blvd., Suite 925
Bethesda, MD 20817
Website: www.hfsa.org Email: info@hfsa.org

Customer Support
For support related to this site, please contact: {{$platformInstance.support.email}} or Toll Free: 877‐796‐1325

Privacy Policy
The website is provided by the Heart Failure Society of America (HFSA). HFSA only obtains personal information that you provide through your participation in this educational activity. Information is collected and retained solely for the purpose of identifying those who have participate and completed this activity. Your personal information will not be sold to any other entity.